Samareh Azeredo da Silveira
Managing Director
Samareh is an early-stage drug development specialist. In 2007, she co-founded LASCCO SA, a virtual incubator dedicated to the identification of discovery-stage pharmaceuticals and diagnostics. Since then, she focused on the development of breakthrough technologies in the fields of critical care and infectious diseases. From 2011 to 2018, she was a partner at Sepstone Diagnostics, a spin-off of LASCCO, where she outlicensed a sepsis diagnostic technology to several industrial partners. She holds a PhD in Neurosciences from Ecole Polytechnique Fédérale de Lausanne (EPFL), and authored numerous publications and opinion reviews
Frédéric Lajaunias
Managing Director
Frédéric has over 10 years of experience in early stage development. In 2007, he co-founded LASCCO SA, a biomedical technology development company focusing on discovery-stage pharmaceuticals and diagnostics. Prior to founding LASCCO, Frédéric served at Abbott Laboratories as manager for the Swiss virology division. Before that, he carried out a post-doctoral work at the Geneva University Hospital studying autoimmune disorders.Frédéric holds a PhD in biology (immunology), from the University of Paris VII, and an MBA with a specialization in Entrepreneurship from the University of Geneva.
Toni Perez
Chief Medical Officer
Toni is a MD, specialist in Intensive Care, with diplomas of Pharmaceutical Industry and General Management Program. Prior to joining Combioxin, Toni was Head of Clinical Research of Infectious Diseases at Novartis, Head of Clinical Development of Anti-Infectives at Basilea Pharmaceutica, Area Head of Clinical Research in Oncology at Almirall, Medical Director of Gastro-intestinal track and CNS and a board member at Esteve. He is a consultant to several pharma companies. During is career, Toni has contributed to the development, registration and marketing of medicines in infectious diseases, oncology, CNS, and gastro-intestinal and urinary tracts among others.
Shelly Bustion
Head of Clinical Operations
Shelly is a multinational expert in clinical trial/program and line manager with over 20 years of experience in the pharmaceutical and medical device industries. She has conducted several clinical trials in all development phases and in many therapeutic areas. Shelly has managed team members at strategic program and clinical trial levels. She has in-depth knowledge of the various clinical development areas and has brought 6 products to the market. Shelly is also a lecturer and trainer at the University of Geneva.
Kristen Peterson
Pharmaceutical Development and CMC
Kristen is a pharmaceuticals expert with over 20 years of experience in process and product development of liposomes. She has directed the process development, scale-up and technology transfer of numerous products from early clinical development through commercialization. Kristen held director-level positions in liposomal process development and manufacturing at ALZA. She also held various Engineering positions with Sequus Pharmaceuticals where she was instrumental in the Doxil® manufacturing process development. Prior to Sequus, she worked at Syntex on other sterile controlled release dosage forms. Kristen received her B.S. in Chemical Engineering from the University of California, Berkeley.
CLINICAL ADVISORS
Dr. Bruno François, MD
Dr. François is specialist in Intensive Care medicine and Anaesthesiology at the University Hospital of Limoges, France. He is the Head of the Limoges Clinical Investigational Center of which the main expertise is in Infectious Disease in critically ill patients. He has been national coordinator for several emergency trials especially in Sepsis, VAP, independent Clinical Evaluation Committees and Adjudication Committees. He has an expertise in the practical bedside organization of clinical research in the ICU. He is actively investigating the role of bacterial resistance mechanisms in sepsis.
Prof. Jérôme Pugin, MD
Prof. Pugin is Head of the Intensive Care Division at the University Hospitals of Geneva, Switzerland. Specialised in internal medicine and intensive care medicine, he shares his time between clinical work and research in the Department of Microbiology and Molecular Medicine at the Faculty of Medicine of the University of Geneva. He is currently Vice President of the French Intensive Care Society. Since 2011, he is Vice-Dean of the Faculty for Clinical Medicine.
Prof. Jordi Rello, MD
Prof. Rello is Head of the Critical Care Department, Hospital Vall d’Hebron, and Professor of Medicine at University Autonoma of Barcelona, Spain. He was trained on clinical epidemiology at Harvard Medical School and was awarded with Investigator Awards of the American College of Chest Physicians and IDSA. He pioneered therapeutic studies for VAP and SCAP. He was president of the Catalonian Society of Critical Care, Chair of the Infection Section at the European Society of Intensive Care Medicine. He is founder and current chair of the critically ill patient study group at the ESCMID society, and Head of the Working Group on Pneumonia and Director of Research Group of CIBERES. He published more than 400 scientific articles and serves in the editorial board of various medical journals.
Prof. Jean Chastre, MD
Prof. Chastre is a Professor of Medicine at Paris VI University School of Medicine in Paris, France. He is also the Director of the Medical Intensive Care Unit, Groupe Hospitalier Pitié-Salpêtrière in Paris, France. He is a recognized expert in the performance of clinical outcomes research in the ICU setting, and his clinical research focus has been the understanding, diagnosis, and treatment of nosocomial pneumonia and the improved care of mechanically ventilated patients. He has published over 170 peer-reviewed papers, and authored 18 book chapters.
Prof. Steven M. Opal, MD
Dr. Opal is a Professor at Alpert Medical School, Brown University in Providence, RI. with a training in Internal Medicine and Infectious Disease. Dr. Opal’s interests are in septic shock research, molecular signaling pathways, microbial toxins and mediators, and antibiotic resistance. Clinical trial design and analyses in phase I to phase III trials are his primary clinical research focus. He has published over 250 peer-reviewed, research papers, over 100 editorials and authored over 90 book chapters in infectious diseases and critical care medicine. He is past chair of the International Sepsis Forum and is a fellow of the Infectious Disease Society of America.
Prof. Pierre-François Laterre, MD
Prof. Laterre is Head of the Intensive Care Unit at St. Luc University Hospital, Université Catholique de Louvain in Brussels, Belgium. His professional and scientific activities have focused on the diagnosis, investigation and treatment of sepsis, severe Community Acquired Pneumonia, liver failure, and ARDS. Prof. Laterre lectures widely, acts both as reviewer and editor for several major scientific journals, and is author of many publications. Prof. Laterre is President of the French Intensive Care Society and member of the European Society of lntensive Care medicine, the Belgian Society of lnfectious Diseases and the Belgian Society of lntensive Care medicine.